Keyword: Sagent Pharmaceuticals

Catalent has invested $9 million in a clinical supply facility and Sagent has access to expanded manufacturing in Canada.

Japan’s Nichi-Iko Pharmaceutical and its U.S. operation Sagent Pharmaceuticals have bought a plant in North Carolina from Xellia.

Sagent Pharmaceuticals issued the recall after detecting higher-than-specified impurities during routine quality testing.

Sagent Pharmaceuticals ($SGNT) is widening its recall of antibiotics manufactured by one of its India-based contractors after a customer complained that small, dark particulate matter were found in the solution after it was reconstituted.

This year’s stock market hasn’t been easy for pharma. Unwelcome news has sent some drugmakers' shares tumbling--as much as 72%, in one notorious case.

Sagent Pharmaceuticals will soon have a new Japanese owner, but for now any recalls are all on the U.S. injectable drug manufacturer. And it has another recall to deal with, this one of an antibiotic manufactured by one of its contractors in India.

Japan’s Nichi-Iko Pharmaceutical has a pipeline of biosimilars it hopes to sell in the U.S. and figures a beachhead there can only help. To enhance its chances, the drugmaker has struck a deal to acquire U.S. sterile injectables maker Sagent Pharmaceuticals for nearly three-quarters of a billion dollars.

Teva is jumping through hoops to close its $40 billion-plus deal for Allergan’s generics unit--but how well will the unit actually perform?